RecruitingPhase 4NCT07485283

Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia

Studying Infectious disease of the nervous system

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tor Biering-Sørensen
Principal Investigator
Tor Biering-Sørensen, MD, PhD, MSc, MPH, MD
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
Intervention
Recombinant Herpes Zoster Vaccine (Shingrix)(biological)
Enrollment
162000 enrolled
Eligibility
65 years · All sexes
Timeline
20262029

Study locations (2)

Collaborators

GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07485283 on ClinicalTrials.gov

Other trials for Infectious disease of the nervous system

Additional recruiting or active studies for the same condition.

See all trials for Infectious disease of the nervous system

← Back to all trials